# CORRESP — Spyre Therapeutics, Inc.  (SYRE)  (CIK 0001636282)

> <strong>Spyre Therapeutics, Inc.  (SYRE)  (CIK 0001636282) → SEC staff</strong> · filed 2026-02-25 · ticker SYRE · SIC 2834

## What is this

A CORRESP letter is the company's written reply to the SEC during a filing review. Responses include accounting position arguments, restatement assessments, and clarifying disclosures. Released to EDGAR alongside the SEC's UPLOAD letters.

## Key facts

- **Accession number:** 0001628280-26-011614
- **Form:** CORRESP
- **Filer:** Spyre Therapeutics, Inc.  (SYRE)  (CIK 0001636282)
- **CIK:** 0001636282
- **Ticker:** SYRE
- **Filed:** 2026-02-25
- **SIC industry:** 2834
- **HQ:** Waltham, MA

## Primary source

PDF letter: https://www.sec.gov/Archives/edgar/data/1636282/000162828026011614/filename1.htm

EDGAR review history for this filer: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1636282&type=UPLOAD&dateb=&owner=include&count=40

## Other comment-letter activity for Spyre Therapeutics, Inc.  (SYRE)  (CIK 0001636282)

- UPLOAD — 2026-02-25 — /comment-letter/0000000000-26-001931

## Citation

> US Securities and Exchange Commission, EDGAR CORRESP comment letter, Spyre Therapeutics, Inc.  (SYRE)  (CIK 0001636282) (CIK 0001636282), filed 2026-02-25, accession 0001628280-26-011614. Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/comment-letter/0001628280-26-011614.

---

*[SEC comment letters dataset](/datasets/sec-comment-letters) · CC0 1.0*